Suppressing Factor VIII Autoantibodies in Hemophilia

Stable remission after first-line therapy was more likely with steroids plus cyclophosphamide than with steroids alone or rituximab-based regimens.

Autoimmune hemophilia is a devastating disorder caused by autoantibodies that inactivate factor VIII (FVIII), resulting in recurrent hemorrhages into skin, muscle, and internal organs. Bleeding is treated with agents that bypass the need for FVIII and is cured by eradicating the FVIII inhibitor. The most common treatments are steroids alone (S), steroids plus cyclophosphamide (S+C), and regimens based on rituximab (R).

To compare the effectiveness of these treatments, investigators analyzed data from the European Acquired Haemophilia Registry on 276 recent patients with autoimmune hemophilia: 142 received S, 83 received S+C, and 51 received R.

Results were as follows:

Complete remission — defined as antibody undetectable and FVIII >70 IU/dL — …

Reviewing Author

David Green, MD, PhD

Disclosures

EquityNovartis

David Green, MD, PhD

Disclosures

EquityNovartis